Webinar: Strategic approaches for first-in-human (FIH) studies and early clinical development
48:56
Description
Related Videos
View More
View Less
48:56
A drug's propensity to cause QT prolongation has to be carefully evaluated in the course of clinical development, and until recently, regulators have required a designated study, the thorough QT (TQT) study, to rule out a small QT effect. It has howe
1:00:02
56:50
45:28